GILEAD SCIENCES INC
Q2 2025 Form 13-F

Description and Activity

Gilead Sciences operates in the biopharmaceutical industry, focusing on developing medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, cancer, and inflammation. Its product lineup includes HIV treatments like Biktarvy® and Descovy®, hepatitis medications such as Epclusa® and Vemlidy®, and the COVID-19 treatment Veklury® (remdesivir). In oncology, Gilead offers CAR T-cell therapies like Yescarta® and Tecartus®, along with Trodelvy® for certain breast cancer types.

Gilead generates revenue primarily through the sale of its pharmaceutical products, with a significant portion of its income derived from large wholesalers in the U.S. The company also benefits financially from royalties and contract revenues through collaborations and licensing agreements. Gilead's primary customers include large wholesalers, healthcare providers, and patients requiring its specialized treatments.

The operational structure of Gilead includes multiple manufacturing facilities located in California, Maryland, and other international sites, with a substantial reliance on contract manufacturing organizations. Research and development are key factors impacting Gilead’s business performance, as the company invests significantly in advancing its pipeline of therapies. Gilead's market position is influenced by competition from other pharmaceutical companies and the need for patent protections to maintain its competitive edge.